News Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
50.85 ^USD	-1.15%		+14.81%	+37.58%

Jun. 07	Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating	MT
Jun. 07	HC Wainwright Raises Price Target on Halozyme Therapeutics to $65 From $50, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating	Jun. 07	MT
HC Wainwright Raises Price Target on Halozyme Therapeutics to $65 From $50, Maintains Buy Rating	Jun. 07	MT
The job report just threw a spanner in the works	Jun. 07
Piper Sandler Downgrades Halozyme Therapeutics to Neutral From Overweight, Adjusts Price Target to $51 From $48	Jun. 07	MT
ANALYST RECOMMENDATIONS : Lyft, Amazon, Fedex, Xpo, Unilever...	Jun. 07
Halozyme Therapeutics Lifts 2024 Guidance -- Shares Surge	Jun. 06	MT
Stocks in motion: Smartsheet, Instacart, Nio...	Jun. 06
Sector Update: Health Care Stocks Steady Premarket Thursday	Jun. 06	MT
Halozyme Therapeutics : Investor Update	Jun. 06	PU
Halozyme Therapeutics Lifts 2024 Guidance; Shares Rise Pre-Bell	Jun. 06	MT
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook	Jun. 06	PR
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024	Jun. 06	CI
Transcript : Halozyme Therapeutics, Inc., 2024 Guidance/Update Call, Jun 06, 2024	Jun. 06
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	Jun. 06	AQ
Halozyme Therapeutics Gets European Patent for Enhanze Drug Delivery Platform	Jun. 05	MT
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform	Jun. 05	PR
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 04	PR
Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing	May. 22	MT
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®	May. 21	PR
Halozyme to Participate in Upcoming Investor Conferences	May. 08	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Summary

Filters